ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Atara Biotherapeutics, formed in October 2012 with licenses for six Amgen drug candidates, has raised $38.5 million in its second round of fund-raising. Celgene, Amgen Ventures, and EcoR1 Capital have joined existing investors including Kleiner Perkins Caufield & Byers. Few details were provided about the six Amgen assets when they were launched. Atara is now describing three candidates, two of which have development plans. Pinta 745, a myostatin-inhibiting peptibody, will enter a Phase II study of treating muscle wasting in patients with end-stage renal disease. And Atara plans to start a Phase I study of STM 434, an activin inhibitor to treat ovarian cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X